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A new encapsulated liquid preparation of methoxsalen 
(8-MOP) and a commonly used crystalline preparation 
(Oxsoralen) were compared in 12 subjects. Each subject 
ingested 0.6 mg/kg body weight of each formulation on 
different days. Six subjects ingested a low-fat meal be-
fore ingestion of drug, and 6 subjects ingested a high-
fat meal. Photosensitivity was tested from 1/2 to 6 h after 
ingestion of 8-MOP by exposure to 320-400 nm radia-
tion (UV A) from a filtered xenon arc lamp. A series of 
graduated doses of UV A were administered at each time 
point to determine the minimum phototoxic dose (MPD) . 
Ingestion of 8-MOP and grading of erythema were con-
ducted in a double-blind manner , and bilaterally sym-
metrical exposure sites were used to test each prepara-
t ion. The phototoxic reaction was observed at 24, 48, 
a nd 72 h by two experienced observers who were una-
ware which formulation had been ingested. The two test 
days were separated by 48 h. 
The encapsulated liquid preparation induced greater 
photosensitivity than Oxsoralen (mean MPDs ± SD: 7.1 
± 4 .7 vs 12.9 ± 6.7 J/cm2 , respectively; n = 12; p < 
0.05). The encapsulated liquid preparation also induced 
photosensitivity earlier than Oxsoralen (mean hours 
after ingestion to achieve peak photosensitivity ± SD: 
2.1 ± 1.2 vs 3.9 ± 1.6, respectively; n = 9; borderline 
s ignificance). On a low-fat diet the encapsulated liquid 
peaked 2.5 h earlier than Oxsoralen, as well as showing 
the shortest a nd the most predictable period of photosen-
sitivity . However, overall, the degree and time of peak 
photosensitivity induced by e ither preparation were un-
affected by diet. Ingestion of the encapsulated liquid 
induced photosensitivity in all 12 subjects; Oxsoralen 
failed to sensitize 3 subjects. Side effects were similar 
after both preparations. 
A new encapsulated liquid preparation of 8-MOP may 
thus a llow lower doses of UVA to achieve therapeutic 
results in photochemotherapy, and a shortened waiting 
period following ingestion of drug. 
Ora l methoxsalen photochemotherapy, in t roduced in 1974 
[1), is n ow a well-establi sh ed m ethod of t reatm ent. The var ia -
bi li ty in a bsorp t ion kinetics a nd bioactivity of some co mmonly 
used crystalline preparations of 8- m ethoxypsoralen (8- MOP) 
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has been well documented (2]. A n ew preparation of 8 -MOP , a 
solutio n enclosed in a soft gelatin caps ule, has b een developed. 
Recent reports h ave s hown t h at a n encapsulated liquid prepa-
ration induces a highe r serum co ncen trat io n of 8 -MOP than a 
c rysta lline preparation (3]. Based o n serum levels after a liquid 
so lution of 8-MOP, investigators have cla imed a greater bioa-
vai la bili ty for a liquid solu t io n (4]. We ha ve compared t he 
photose ns it izin g e ffect, using ph ototox ic erythe ma as a ma rker, 
of a n e ncapsulated liqu id preparation with t hat of a standard 
c rystalline (co mme rc ia lly available) preparation of methoxsa-
le n , Oxsora len , in 12 norma l subjects by administeri ng each 
preparatio n to each subject o n different days, a nd us ing a 
doub le-blind, bilaterally symmetri cal compa rison technique. 
The use of t he minimum phototoxic dose (MPD) of UVA as ali 
experime n ta l e nd point establis hes t he clinical re levance of t he 
data. W e have a lso investigated t he role of diet o n t he photo-
sens itiz in g e ffect of eac h prepa ratio n of 8-MOP. 
MATERIALS AND METHODS 
Volun.tee rs 
Twelve fair-skinned human subjects (sk in types I- ll ) were used in 
th is study: 9 were women a nd 3 were men. All were healt hy and taking 
no medicat ions. Ages ranged from 18- 28 years. Informed consent was 
obtained. 
Drugs 
Two different preparations of 8-MOP were tested. One was Oxsor-
alen, a crystalline preparation in a hard capsu le; the other was a liquid 
preparation of 8-MOP enclosed in a soft gelatin capsule. Each capsule 
conta ined 10 mg 8- MO P. Both preparations were supplied by Thomas 
B. Elder Co., Bryant, Ohio. Each volunteer ingested 0.6 mg/ kg body 
weight of 8-MO P of one of the preparations on the fi rst test day of the 
experiment, and the same dose of t he other prepa ration on the second 
test day of the experiment.. The two test days were separated by 48 h. 
All vo lunteers ingested t he 8-MOP in front of personnel not involved 
in exposures or readings. 
UV Sources 
T he source of ul t rav iolet radiation was a 2500- W xenon arc lamp, 
filtered t hrough a CuSO,/CoSO, liquid !ilter and a glass cut-off !ilter 
to produce broadband ul t raviolet-A radiation (UVA) (320- 400 nm ), 
peaking at 365 nm . The average irradiance of the source was 25 m WI 
cm2 ± 7%. The fi eld produced was a circle 8 em in diamete r. 
Exposure Doses an.d P rocedure 
Thirty minutes afte r ingestion of 8-MOP, a n 8 X 8 em template 
conta ining 9 1-cm exposure sites was taped on one s ide of the subject's 
back, and a series of graduated UVA doses administered to the area. 
Sites received 1.4, 2.0, 2.8, 3.9, 5.4, 7.6, 10.7, 15, or 21 J j cm2 , adminis-
tered in a total of 15 min . T he template was then moved to a different 
a rea on the same side of t he back and the irradiation procedure repeated 
1, 1.5, 2, 3, 4, 5, and 6 h after ingestion of 8-MOP. Thus, on a test day, 
a series of 9 exposure doses was given 8 t imes on one side of the back. 
Forty-eight hours late r the procedure was repeated fo llowing ingestion 
of the other 8-MOP preparation by t he same individual. Bilatera lly 
symmetrical sites on the other side of the back were used on t he seco nd 
test day. In this way, the degree, t ime, and duration of photosensitivity 
were determined for each subjecl. 
T he dose of UV radiation necessary to induce a 1 +erythema (min -
imal uniform erythema with clearly defined borders) after ingestion of 
drug a nd exposure to UV radiation is ca lled the minimum phototoxic 
186 LEVINS ET AL 
dose (MPD) . Thus, t he MPD , measured at a ny t ime poin t, is a t hreshold 
dose of UV radiation, expressed in joules/em'. 
Twenty-four, 48, a nd 72 hours afte r each experimenta l day, t he 
exposure s ites were observed to determine the MPD at each irradiat ion 
time poin t . All observations were made by two experie nced observers 
who were unaware of which preparation of 8- MOP t he vo lun teers had 
taken . 
The peak photosensitivity was defined as the occurrence of the 
lowest MPD , at whateve r time point it occurred; in this study a ll MPDs 
were measured at 72 h since all phototoxic reactions peaked at t hat 
t ime. 
Diet 
Each vo lun teer fasted for 8 h before the study. S ix vo lun tee rs 
received a low- fat breakfast immediate ly before ingestio n of 8-MOP, 
consisting of 1/2 pint of low- fat milk a nd 2 pieces of unbuttered toast. 
The other 6 volun teers received a high-fat break fast immediately before 
ingestion of 8-MOP, cons isting of 2 slices of bacon , 2 eggs, 2 pieces of 
but tered toast, a nd 112 pint of whole milk. All vblun tee rs received the 
same lunch (ham a nd turkey sandwich a nd milk) not less than 4 h 
afte r ingestion of 8- MOP. 
RESULTS 
Photosensitivity (M PDs) 
The mean of the lowest MPDs after the liquid preparation 
was approximate ly 40% lower than the mean of the lowest 
MPDs afte r t he crystalline formulation (Table I). This differ-
ence was significant (p < 0.05). In 3 subjects, an MPD was not 
reached at any t ime after ingestion of crysta lline 8-MOP; 22 J / 
em' was assigned as the MPD for statistical purposes in t hese 
individua ls, alt hough MPDs were reached after the liquid prep-
a ration in all 3 subjects. Diet did not significant ly influence the 
mea n MPD induced by t he liquid formu lation or the mean 
MPD induced by the crystalline formulati on. 
The ra t io of liquid MPD/crystalline MPD was also calcu lated 
for each subject, and t he mean ratio calcu lated for each dietary 
group. 
T ime of Pea.h Photosensitivity 
For each subject, the interval from t ime of ingestion of each 
prepa ratio n of 8- MOP to t he occurrence of peak photosensit iv-
ity was ca lculated, and t he mean interval obtained for each 
dietary group. T he encapsulated liquid induced ea rlier photo-
sensitization in both dietary groups; t he difference was s ignif-
icant only in the group receiving the low- fat diet (Table II). 
Liqu id 8-MOP -induced photosensitivity peaked 2.5 ± 2.3 h 
ea rli er than crystalline 8- MOP-induced photose nsitivity in t he 
low-fat diet group , compared with 0.75 ± 0.96 h ea rlier in the 
high-fat diet group. 
Incidence of Nausea 
One subject reported nausea a fter a low- fat meal and inges-
t ion of li quid 8-MOP; 1 subject vomited 35 min a fte r a low-fat 
TABLE l. Peah photosensitivity ( M P Ds) 
Liquid Crystalline 
Low- fat diet 7.5 ± 5.9 p < 0.05 11.9 ± 6.0 
(n = 6) (n + 6)" 
n. s. n. s. 
6.7 ± 3.6 p < 0.05 13.9 ± 7.8 
(n = 6) (n = 6jl' 
High -fat diet 
All subjec ts 7.1 ± 4.7 p < 0.05 12.9 ± 6.7 
(n = 12) (n = 12) 
Paired compa rison of liquid MPD/crysta lline MPD ra tio: 
Low- fat diet: 0.59 ± 0.27 
High-fat diet: 0.67 ± 0.67 
All subjects: 0.63 ± 0.49 
" Not reached in 1 subject, va lue taken as 22 J /c m2 for stati stical 
a na lys is. 
b Not reached in 2 subjects, values taken as 22 J /cm2 for statis tica l 
a nalys is. 
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TABLE II. T ime of occurrence of lowest MPDs in hours after ingestion 





1.67 ± 0.8 
(n = 5) 
2.5 ± 1.5 
(n = 6) 
2.1 ± 1.2 
(n = 12) 
"Not reached in 1 subject. 
1





4.2 ± 1.6 
(n = 5)" 
3.5 ± 1.7 
(n = 4)h 
3.9 ± 1.6 
(n = 9) 
meal and ingestion of li quid 8-MOP; and 1 subject reported 
nausea after a high -fa t meal and crysta lline 8-MOP (Table III ). 
It is apparent t hat there was no significant difference in the 
s ide effects associated with the use of the liquid vs t he crystal-
line formu lation. The subject who vomited 35 min after inges-
tion of liquid 8-MOP still showed marked photosensitivity 
(Table Ill). 
DISCUSSION 
Recently t he term bioavailability has been used to denote t he 
se rum [4] and plasma [5]levels of 8-MOP after oral ingestion. 
We use t he term bioactivi ty to denote the actual photosensit iz-
ing effect of 8-MOP. Although within individuals an inverse 
correlation between se rum levels of 8-MOP and t he MPD has 
been reported [6]. isolated se rum levels of 8-MOP have not 
generally been useful in predict ing photosensitivity. Cutaneous 
phototox icity, as assessed by MPD, is t herefore probably a 
more appropriate measurement for the clinical evaluat ion of 
the bioactivity of 8-MOP. We have made a direct comparison 
at se ria l time points, in t he same individua ls a nd with a 
contro ll ed diet, of t he photosensit izing effect of both a liquid 
and a crysta lline preparat ion of 8-MOP, using the MPD of 
UV A as our end point. 
H i:inigs mann et a l [7] reported a 25% reduct ion in MPD 
when pso riat ic patients were tested 1 h after ingestion of a 
liquid capsule prepa ration as compa red with the MPD meas-
ured 2 h a fter a conventional crystalline preparation. However, 
no other time points were reported , and wide individual varia-
t ions in t he time of peak photosensitivity after ingestion of 
crystalline 8-MOP are well-known. 
We tested each subject at 8 differen t t ime points and report 
a 40% reduction in the lowest MPD, when a liquid and a 
crystalline preparation are compared. Interestingly, Hi:inigs-
mann et al [7] reported a 40% reduction in cumulative UVA 
dose to clear in liquid 8-MOP-treated vs crystaiiLne 8-MOP-
t reated psoriatic patients. Current protocols call for UV A ex-
posure 2 h a fter ingestion of 8-MOP, usually Oxsoralen. We 
observed peak photosensitivity 3.5- 4.2 h after ingestion of 
Oxso ralen. Van Weelden et al [8] a lso reported a s imila r 
maximal photosensitivity between 3 and 4 h after ingestion of 
crysta lline 8-MOP, and reported a 50% reduction in exposure 
dose in treatment of psoriasis by switching UVA irradiation 
from 2 to 3 h afte r 8-MOP ingestion. Although a liquid 8-MOP 
formul ation or adoption of a 3 to 4-h post -Oxso ralen exposure 
time cou ld be used to reduce cumulative UV A dosage, the 
amount of psoralen-induced phototoxicity would remain the 
same. While UVA sparing is presumably desirable, the long-
term effects of pso ralen-induced phototoxicity are sti ll un-
known. 
The duration of the photosensit ive state is an important 
facto r in safe and effective t herapy. A short, sensit ive period is 
probably preferable to a longer and less sensitive state. Envi-
ronmental exposure is a common hazard for many PUV A 
patients. The shortest and most predictable photosensitive 
period was seen in t he low-fat diet, liquid 8-MOP group. In 
contrast, the same subjects ingesting t he same diet showed a 
much longer duration of photosensitivity following crystalline 
8-MOP. However, a short period of photosensitivity may give 
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TABLE III. Dose of UVA in J /cm" necessary to cau.se I+ erythema 72 lwu.rs after exposure (MPD) (the lowest MPD in each series is underlined) 
Volunteer Diel 8-MOP 
'h h I h l'h h 
#1 Low- fat Liquid 3.9 3.9 2.0 
Low-fat Crystal >21 >21 >21 
#2 Low-fat Liquid 5.4 5.4 5.4 
Low-fat Crysta l >2 1 >21 21 
#3 Low-fat Liquid 5.4 7.6 15 
Low-fat Crysta l >21 >2 1 >2 1 
#4 Low-fat Liquid >21 5.4 3.9 
Low-fat Crystal >2 1 >21 21 
#5 Low-fat Liquid >21 >2 1 15 
Low-fat Crysta l >21 >21 >21 
#6 Low-fat. Liquid >2 1 >2 1 >21 
Low-fat Crystal >21 >2 1 >2 1 
#7 High-fat Liquid >21 21 10.7 
High-fat Crystal >21 >21 >21 
#8 High-fat Liquid >2 1 10.7 10.7 
High-fat Crysta l >2 1 >21 >2 1 
#9 High-fat Liquid >2 1 >2 1 21 
High -fat Crysta l >21 >2 1 >2 1 
#10 High -fat Liquid >21 >2 1 >21 
High -fat Crysta l >2 1 >2 1 >2 1 
#11 High-fat Liquid 10.7 2 2.8 
High-fat Crysta l >21 >21 >21 
#12 High-fat Liquid >21 7.6 7.6 
High-fat Crystal >21 >21 10.7 
ri se to problems in t he precise timing of t reatments, which 
would limit t he optimum utili zat ion of the e nca psula ted liquid . 
Different e ffects of diet on blood levels o f 8-MOP have been 
reported in the li te rature. Swanbec k et a l [9] reported higher 
peak plasma co ncen trations of 8-MOP under fasting vs non -
fast ing co ndi t ions, a lthough t he ti mes at which peak levels 
occurred were not s ignificantly different. H erfst et a l [10] 
reported only a s li ght difference in the s ize of peak se rum leve ls 
in fasting a nd nonfastin g volunteers, although under fasting 
condi t ion peak se rum leve ls occurred earlier. We report no 
s ignificant difference in e ither degree of pea k photosensitivity 
or t ime of peak photosensitivity within t he Oxsoralen group, 
o r w it hin t he e ncapsu lated liquid group, when a high-fat meal 
is compared to a low- fat meal. H owever, there may be a s ma ll 
a d van tage in ingesting a low-fat meal before a liquid 8-MOP 
preparation, s ince this appears to result in a mo re consiste n t 
photosensitivity. 
This study has s how n that a new liquid preparation of 8-
MOP has a greater photose ns it izi ng ab ility t ha n Oxsoralen. 
We have studied the effect o f diet a nd suggest t hat standard-
ization may a llow mo re re lia ble treatment. This new prepara-
t ion of encapsul ated liquid 8-MOP may improve t he effi cacy 
and safety of photochemotherapy. 
The authors gratefu lly ack nowledge t he expert technical assistance 
of Naomi Kagetsu, and statistica l analys is by Meg Mandelson and 
Robert Stern , M.D. 
Time After Pills Nau•ea 
2 h :1 h 4 h 5 h (ih incident 
:3.9 2.8 7.6 7.6 21 
21 10.7 10.7 7.6 10.7 
3.9 5.4 15 15 >21 ++(vomit) 
7.6 10.7 7.6 5.4 10.7 
15 15 15 15 >2 1 
>21 >21 >21 >21 15 
3.9 .5.4 21 >21 >21 + 
7.6 10.7 21 >2 1 >21 
21 >2 1 >21 >2 1 >2 1 
>21 >21 >2 1 >21 >21 
>21 15 >21 21 15 
21 15 15 15 21 
5.4 :1.9 7.6 15 >21 
>21 21 >21 >2 1 >21 + 
10.7 15 >2 1 >2 1 >2 1 
>2 1 >2 1 >21 >21 >21 
15 7.6 >2 1 >21 >21 
>21 >21 >2 1 >21 >21 
>2 1 >2 1 21 10.7 10.7 
>2 1 >21 10.7 5.4 
3.9 5.4 10.7 >21 >21 
1.5 7.6 10.7 15 >2 1 
5.4 7.6 21 >21 >2 1 
7.6 10.7 >2 1 >2 1 >21 
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